The US Food and Drug Administration (FDA) has granted 510(k) clearance for Quidel‘s AmpliVue hand held molecular diagnostic test for the detection of Bordetella pertussis.

Pertussis is a contagious disease caused by the Bordetella pertussis bacteria, which attaches to the cilia that line part of the upper respiratory tract where they cause inflammation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition, Quidel will be able to promote AmpliVue Bordetella Assay, a self-contained, handheld disposable molecular diagnostic test with advanced clinical accuracy.

The company said the assay does not require direct extraction of DNA and delivers precise results in 75 minutes.

Quidel president Douglas Bryant said: “We are pleased to receive 510(k) clearance for our AmpliVue Bordetella Assay, our fifth assay in the AmpliVue format.

“The new assay will be able to detect Bordetella pertussis nucleic acids separated from nasopharyngeal swab specimens taken from patients suffering with respiratory tract infection attributable to Bordetella pertussis.”

“We have shown that we can harness our proprietary Helicase Dependent Amplification (HDA) technology to develop fast, accurate molecular diagnostic assays with a menu that matters to our customers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Longer-term, we intend to leverage this technology for other molecular diagnostic applications that will be appealing to significant market segments and potentially to public health agencies worldwide.”

The new assay will be able to detect Bordetella pertussis nucleic acids separated from nasopharyngeal swab specimens taken from patients suffering with respiratory tract infection attributable to Bordetella pertussis.

Classified by Clinical Laboratory Improvement Amendments (CLIA) as moderately complex, the new assay is similar to other FDA approved AmpliVue assays, which makes it unnecessary for consumers to spend money on costly thermocycling apparatus.

With the AmpliVue platform, laboratories of all sizes will be able to execute highly sensitive and precise molecular tests.

In addition, the AmpliVue Bordetella Assay joins already approved detectable analytes including Pertussis, C difficile, Group A Strep, Group B Strep, HSV1 and HSV2.